Get the Stockscreener App
36.74
0.14%
0.05
After Hours:
36.74
Tandem Diabetes Care Inc stock is traded at $36.74, with a volume of 768.89K.
It is up +0.14% in the last 24 hours and down -1.65% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$36.69
Open:
$36.8
24h Volume:
768.89K
Relative Volume:
0.63
Market Cap:
$2.41B
Revenue:
$796.00M
Net Income/Loss:
$-136.49M
P/E Ratio:
-17.58
EPS:
-2.09
Net Cash Flow:
$-64.24M
1W Performance:
-0.73%
1M Performance:
-1.65%
6M Performance:
-15.33%
1Y Performance:
+52.01%
1-Day Range:
$36.63
$37.71
1-Week Range:
$35.62
$37.93
52-Week Range:
$22.03
$53.69
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
36.74 | 2.41B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
128.22 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.02 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
396.07 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.99 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Jennison Associates LLC Lowers Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
KBC Group NV Grows Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
Chicago Capital LLC Sells 32,540 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
(TNDM) Trading Advice - news.stocktradersdaily.com
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock? - MSN
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Beacon Investment Advisory Services Inc. Cuts Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
Infusion Devices Market to Reach US$ 23.08 Billion by 2031, Driven by Rising Prevalence of Infectious Diseases - GlobeNewswire Inc.
Artificial Pancreas Market is Predicted to Achieve Huge Growth - openPR
Assenagon Asset Management S.A. Decreases Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
Reasons to Retain TNDM Stock in Your Portfolio for Now - MSN
Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 4%Time to Sell? - MarketBeat
Is There An Opportunity With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 47% Undervaluation? - Simply Wall St
(TNDM) Long Term Investment Analysis - Stock Traders Daily
Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
Tandem Diabetes Care Sets Q4 and Full Year 2024 Earnings Release for February 26 - StockTitan
JPMorgan Chase & Co. Buys 113,355 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
UVA Center for Diabetes Technology, Tandem Diabetes Care to Research Fully Automated Insulin Delivery - Cville Right Now
Tandem Diabetes Forges New R&D Agreement With UVA: Stock to Gain? - MSN
Advancing R&D of fully automated insulin delivery systems - Today's Medical Developments
automated insulin delivery systems - Today's Medical Developments
UVA Center for Diabetes to participate in research of auto insulin delivery - Augusta Free Press
When (TNDM) Moves Investors should Listen - Stock Traders Daily
Tandem inks collab with UVA to develop closed-loop automated insulin delivery tech - Drug Delivery Business News
Tandem Diabetes Care, Inc. Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems - Marketscreener.com
Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems - BioSpace
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Principal Financial Group Inc. Sells 77,771 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
How the (TNDM) price action is used to our Advantage - Stock Traders Daily
Is Tandem Diabetes Care (NASDAQ:TNDM) Weighed On By Its Debt Load? - Simply Wall St
Insulin Pump Market Insights: Key Drivers, Competitive - openPR
ROSEN, A TOP RANKED LAW FIRM, Encourages Tandem Diabetes Care, I - GuruFocus.com
Insulin Pump Market Valuation to Jump to Reach US$ 25.40 Billion by 2033 | India and China Offering Lucrative Growth Opportunities Says Astute Analytica - Yahoo Finance
Geode Capital Management LLC Has $64.72 Million Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
New partnerships, approvals pump prospects for insulin delivery devices - BioWorld Online
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada - MSN
Where are the Opportunities in (TNDM) - Stock Traders Daily
Barclays PLC Sells 174,647 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
State Street Corp Has $112.63 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) - MarketBeat
Tandem Diabetes Care's SWOT analysis: stock outlook amid product innovation and market expansion - Investing.com Canada
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.14%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):